UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 28, 2012
SYNAGEVA BIOPHARMA CORP.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 0-23155 | | 56-1808663 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
128 Spring Street, Suite 520, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 357-9900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into a Material Definitive Agreement. |
On February 28, 2012, Synageva BioPharma Corp. (“Synageva”) entered into a Biopharmaceutical Services Agreement (the “Agreement”) with Cytovance Biologics, Inc., a Delaware corporation (“Cytovance”). Cytovance will purify clinical trial material for SBC-102, Synageva’s most advanced pipeline program, from protein provided by Synageva. The Agreement will remain in effect until Cytovance completes the projects mutually agreed to by the parties and Synageva will pay Cytovance incremental amounts for each phase of the development process. Synageva may terminate its agreement with Cytovance upon 60 days’ written notice, but Cytovance may only terminate the agreement in the event of a material uncured breach by Synageva.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| SYNAGEVA BIOPHARMA CORP. |
| |
| By: | | /s/ Sanj K. Patel |
| | Sanj K. Patel |
| | President and Chief Executive Officer |
Date: March 5, 2012
